Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...

Among 475 patients randomized in a 1:1:1:1 fashion, those on one of three doses of injectable tirzepatide -- 5 mg, 10 mg, or 15 mg -- in addition to insulin glargine saw a significantly greater mean ...

In this study, we examined the pharmacokinetic and pharmacodynamic dose-response effects of single subcutaneous injections of insulin glargine in obese type 2 diabetic individuals. Our study ...

FDA is aware of four recently-published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies ...

New insulin products were the go-to choice for U.S. adults with type 2 diabetes in the last half decade, researchers reported. According to a serial cross-sectional study of ambulatory insulin use ...

After nearly seven months and two prior recalls, Viatris continues to be vexed by labeling issues on its biosimilar to Sanofi’s diabetes blockbuster Lantus. Viatris’ Mylan this week said it was once ...

HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial ...

The authors say there has been a recent uptick in hosptial admissions from hypoglycemic events, and that a therapy to address this is needed. A review of 15 studies has found that insulin degludec, ...

Following review of all available information on a possible relationship between insulin analogues, in particular insulin glargine, and the risk of cancer, the European Medicines Agency's Committee ...

Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog. Semglee ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...